Literature DB >> 30894734

Protein-slaying drugs could be the next blockbuster therapies.

Megan Scudellari.   

Abstract

Keywords:  Drug discovery; Molecular biology; Therapeutics

Mesh:

Substances:

Year:  2019        PMID: 30894734     DOI: 10.1038/d41586-019-00879-3

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  16 in total

Review 1.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

2.  Generation of a live attenuated influenza A vaccine by proteolysis targeting.

Authors:  Longlong Si; Quan Shen; Jing Li; Li Chen; Jinying Shen; Xue Xiao; Haiqing Bai; Tang Feng; Adam Yongxin Ye; Le Li; Chunhe Zhang; Zhen Li; Ping Wang; Crystal Yuri Oh; Atiq Nurani; Siwen Niu; Chengxin Zhang; Xiaoqiong Wei; Wanqiong Yuan; Hao Liao; Xiaojie Huang; Ning Wang; Wen-Xia Tian; Hongwei Tian; Li Li; Xiaoheng Liu; Roberto Plebani
Journal:  Nat Biotechnol       Date:  2022-07-04       Impact factor: 68.164

Review 3.  The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors:  Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal:  Nat Rev Drug Discov       Date:  2022-03-29       Impact factor: 112.288

Review 4.  Ubiquitin ligases: guardians of mammalian development.

Authors:  David A Cruz Walma; Zhuoyao Chen; Alex N Bullock; Kenneth M Yamada
Journal:  Nat Rev Mol Cell Biol       Date:  2022-01-25       Impact factor: 113.915

Review 5.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

6.  Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways.

Authors:  Kurt Reichermeier; Daniel C Scott; Lorena Samentar; Jasmin Coulombe-Huntington; Spencer Hill; Luisa Izzi; Xiaojing Tang; Rebeca Ibarra; Thierry Bertomeu; Annie Moradian; Michael J Sweredoski; Nora Caberoy; Brenda A Schulman; Frank Sicheri; Mike Tyers; Gary Kleiger
Journal:  Elife       Date:  2019-12-23       Impact factor: 8.140

7.  Is PROTAC technology really a game changer for central nervous system drug discovery?

Authors:  Kayla Farrell; Timothy J Jarome
Journal:  Expert Opin Drug Discov       Date:  2021-04-19       Impact factor: 7.050

8.  Systematic characterization of mutations altering protein degradation in human cancers.

Authors:  Collin Tokheim; Xiaoqing Wang; Richard T Timms; Boning Zhang; Elijah L Mena; Binbin Wang; Cynthia Chen; Jun Ge; Jun Chu; Wubing Zhang; Stephen J Elledge; Myles Brown; X Shirley Liu
Journal:  Mol Cell       Date:  2021-02-09       Impact factor: 19.328

9.  How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?

Authors:  Patricia Martin-Romano; Capucine Baldini; Sophie Postel-Vinay
Journal:  JNCI Cancer Spectr       Date:  2019-11-06

Review 10.  Target-Directed Approaches for Screening Small Molecules against RNA Targets.

Authors:  Hafeez S Haniff; Laurent Knerr; Jonathan L Chen; Matthew D Disney; Helen L Lightfoot
Journal:  SLAS Discov       Date:  2020-05-18       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.